Ryo Yanagisawa (Department of Cardiology, Keio University School of Medicine, Tokyo, Japan) and colleagues report in JACC: Cardiovascular Imaging that hypoattenuated leaflet thickening after transcatheter aortic valve implantation (TAVI) is “not rare but usually subclinical”. According to study author Kentaro Hayashida (Department of Cardiology, Keio University School of Medicine, Tokyo, Japan), because of a lack of data, the optimum solution for managing leaflet thickening is still unknown.
Sonny Palmer (St Vincent’s Hospital, Melbourne, Australia) and others report in JACC: Cardiovascular Interventions that left atrial appendage thrombus, as identified with computed tomography (CT), is a common finding among people who have been referred for transcatheter aortic valve implantation (TAVI). They add that the presence of left atrial appendage thrombus may increase the risk of stroke in these patients.
Recently, there has been a move towards transcatheter aortic valve implantation (TAVI) procedures that are more “minimally invasive”. In this interview, Jay Giri (Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, USA) talks to Cardiovascular News about what a minimally invasive TAVI approach involves and its potential risks and benefits. How would you define “minimally invasive” TAVI?
The CE mark has been granted to Medtronic for the 34mm-valve version of its CoreValve Evolut R, the largest sized transcatheter aortic valve implantation (TAVI) system available in Europe. The company also announced the European market launch of the device.
Direct Flow Medical, which markets a CE-marked transcatheter aortic valve implantation (TAVI) device, has closed after funding from a Chinese pharmaceutical company did not come through. According to newspaper The Press Democrat, all 250 company’s employees have been made redundant and it officially ceased trading on 30 November.
Shingo Kuwata (University Heart Center, Zurich, Switzerland) and others report in Eurointervention that atrial fibrillation is a “frequent comorbidity” in patients with mitral regurgitation who are undergoing percutaneous mitral valve repair with MitraClip (Abbott Vascular). Therefore, they evaluated the feasibility of combining a MitraClip procedure with left atrial appendage occlusion using the Amplatzer cardiac plug (St Jude Medical). In this interview, study authors Kuwata, Francesco Maisano and Fabian Nietlispach (all University Heart Center, Zurich, Switzerland) discuss their results.
A medical team from Clínica Universidad de Navarra in Pamplona, Spain, has successfully performed the country’s first implant of the SynCardia temporary Total Artificial Heart.
Heightened activity in the amygdala has been associated with a greater risk of heart disease and stroke, according to a study published in The Lancet that provides new insights into the possible mechanism by which stress can lead to cardiovascular disease in humans.
Following the recent announcement from the American College of Cardiology (ACC) that David J Moliterno is to become the new editor-in-chief of JACC: Cardiovascular Interventions, the society has now named YS Chandrashekhar as the new editor-in-chief of JACC: Cardiovascular Imaging. It says that Chandrashekhar’s term will begin with the July 2017 print issue of the journal and that he replaces Jagat Narula, who has served as editor since the journal first launched in 2008.
According a news report on Mass Device, Boston Scientific has “found a fix” for the problem with its next-generation transcatheter aortic valve implantation (TAVI) device. The company paused implantation of the device in October last year (in Europe, where the device has the CE mark) to investigate a potential problem its locking mechanism.
ACIST Medical Systems has announced that enrolment has been completed in its ACIST-FFR study—Assessment of catheter-based interrogation and standard techniques for fractional flow reserve measurement—which is a multicentre trial that began in November 2015 and includes 240 patients at 12 sites across the USA. Final results are expected to be released in mid-2017.
The American College of Cardiology (ACC) has named David J Moliterno (Jack M Gill Chair, Department of Internal Medicine, University of Kentucky, Lexington, USA) as the new editor-of-chief of the interventional cardiology journal, JACC: Cardiovascular Interventions. An ACC press release states that the journal covers the entire field of interventional cardiovascular medicine and is ranked among the top 10 cardiovascular journals for its scientific impact.
OrbusNeich has launched the Scoreflex NC, a non-compliant scoring balloon targeting more resistant lesions. The product is a focused force dual-wire balloon system built to facilitate controlled plaque modification with strength and accuracy.
A new expert consensus decision pathway will assist clinicians and hospitals in assessing patients’ eligibility for transcatheter aortic valve implantation (TAVI), performing the procedure successfully and providing appropriate follow-up. The “2017 American College of Cardiology (ACC) Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults with Aortic Stenosis” builds on recommendations set forth in the “2014 American Heart Association (AHA)/ACC Guidelines for Management of Patients with Valvular Heart Disease”, and was published the Journal of the American College of Cardiology.
Arterys has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its Arterys Cardio deep learning (DL) application. Arterys Cardio DL leverages cloud computing and deep learning in a clinical setting.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos